Akt

Pifusertib is a selective, orally active allosteric inhibitor of Akt, exhibiting IC50 values of 4.8, 1.6, and 44 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anti-myeloma activity and intensifies lethal endoplasmic reticulum (ER) stress resulting from proteasome inhibition. In addition, Pifusertib promotes both apoptosis and autophagy, making it a useful tool for research in cancer biology and therapeutic development.

MK-2206 is a highly potent and selective allosteric inhibitor of the Akt signaling pathway, exhibiting IC50 values of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anticancer activity, particularly in breast cancer cell lines and those harboring PIK3CA mutations or loss of PTEN function. MK-2206 is valuable for research investigating Akt's role in cancer progression and therapeutic resistance.

Engasertib is a potent and selective inhibitor of AKT1 and AKT2, displaying IC50 values of 0.13 µM and 0.09 µM, respectively, with a slightly lower potency against AKT3 at 2.75 µM. This compound effectively inhibits AKT phosphorylation, leading to modulation of downstream signaling pathways in vitro. Due to its ability to suppress cancer cell proliferation and tumor growth, Engasertib serves as a valuable tool for cancer research and therapeutic development.

H-Ile-Lys-Val-Ala-Val-OH is a potent activator of the MAPK/ERK1/2 and PI3K/Akt signaling pathways. This compound enhances cell adhesion, promotes neurite outgrowth, and supports tumor growth. It is particularly effective in stimulating the proliferation of bone marrow-derived mesenchymal stem cells (BMMSCs), making it valuable for research applications in cell biology and regenerative medicine.

Notoginsenoside Ft1 is a potent PI3K/AKT/mTOR inhibitor with significant bioactive properties. This compound induces apoptosis and lysosomal cell death in various cancer cell types by modulating key signaling pathways, such as p38 MAPK and ERK1/2, while promoting angiogenesis. Additionally, Notoginsenoside Ft1 enhances CD8+ T cell populations and exerts vasodilatory effects through glucocorticoid and estrogen receptor beta activation in endothelial cells. By acting as a TGR5 agonist and FXR antagonist, it may provide protective effects against renal injury and contribute to the management of obesity and insulin resistance through the modulation of intracellular calcium and cAMP levels.

Vevorisertib trihydrochloride is a selective, allosteric inhibitor targeting pan-AKT and the AKT1-E17K mutant. It effectively inhibits AKT phosphorylation, demonstrating Kd values of 1.2 nM for AKT1 and 8.6 nM for AKT1-E17K, along with IC50 values of 0.55 nM, 0.81 nM, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. This compound is valuable for cancer research, aiding in the exploration of therapeutic strategies targeting the AKT signaling pathway.

Pifusertib hydrochloride is a selective allosteric inhibitor of Akt, exhibiting IC50 values of 4.8 nM, 1.6 nM, and 44 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anti-myeloma activity by enhancing endoplasmic reticulum stress in the context of proteasome inhibition. Additionally, Pifusertib hydrochloride induces both apoptosis and autophagy, making it a valuable tool for research into cancer therapies and the modulation of cellular stress responses.

JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms.

N-Acetyldehydroanonaine is a natural alkaloid that functions as a ligand for AKT1 and MAPK1, key regulators in various signaling pathways. This compound, derived from plants of the Zanthoxylum genus, exhibits potential biological activity relevant to cancer research. Its application is particularly significant in the study of diseases such as gastric cancer, making it a valuable tool for investigators exploring therapeutic targets and mechanisms in oncogenesis.

Akt/ROCK-IN-1 is a potent dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively. This compound demonstrates significant antitumor activity, particularly in neuroblastoma models. It serves as a valuable tool for research into cancer biology and therapeutic development.

ML-9 Free Base is a selective and potent inhibitor of Akt kinase, demonstrating significant inhibitory effects on myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). It effectively inhibits MLCK, protein kinase A (PKA), and protein kinase C (PKC) with Ki values of 4 μM, 32 μM, and 54 μM, respectively. Additionally, ML-9 Free Base promotes autophagy by enhancing autophagosome formation while inhibiting their subsequent degradation, making it valuable for research on cellular signaling pathways and autophagic processes.

Miransertib mesylate is a potent and selective allosteric inhibitor of the Akt family, demonstrating IC50 values of 2.7 nM, 14 nM, and 8.1 nM for Akt1, Akt2, and Akt3, respectively. This compound is particularly effective against the AKT1-E17K mutant variant, making it valuable for investigating PI3K/AKT-driven tumors and Proteus syndrome. Additionally, Miransertib mesylate has shown efficacy against Leishmania, highlighting its versatility in biological research applications.

KS-99 is an inhibitor that targets both tubulin polymerization and the Akt signaling pathway. This compound demonstrates significant biological activity by inhibiting cancer cell proliferation and inducing apoptosis in various cancer cell types. KS-99 is suitable for research applications involving colorectal cancer, breast cancer, lung epithelial cancer, and melanoma.

Thyroglobulin is a 660 kDa dimeric glycoprotein that serves as a substrate in the synthesis of thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Primarily produced by follicular cells of the thyroid, it also functions in the storage of inactive thyroid hormone forms and iodine in the follicular lumen. In research applications, thyroglobulin has been shown to activate Akt kinase activity in FRTL-5 thyroid cells, making it valuable for studies related to thyroid function and signaling pathways.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.